The National Institutes of Health (NIH) is conducting a multi-site clinical trial to evaluate Shionogi & Co.’s Xocova COVID-19 antiviral drug to determine its effectiveness in improving care for afflicted individuals. Xocova, also known as ensitrelvir fumaric acid or S-217622, was discovered by Osaka-based Shionogi and Hokkaido University in Sapporo, Japan. The trial will be…